

# Neeraj Agarwal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2886080/publications.pdf>

Version: 2024-02-01

38  
papers

4,113  
citations

567281

15  
h-index

361022

35  
g-index

39  
all docs

39  
docs citations

39  
times ranked

5370  
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
2	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	10.7	1,280
3	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
4	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2474-2485.	1.6	250
5	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	1.6	127
6	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	1.9	99
7	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	2.9	75
8	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
9	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	1.6	69
10	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	1.6	65
11	Macrophage HIF-1 $\alpha$ Is an Independent Prognostic Indicator in Kidney Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4970-4982.	7.0	45
12	Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 365-368.	1.9	38
13	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. <i>Future Oncology</i> , 2022, 18, 425-436.	2.4	28
14	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3017-3027.	7.0	19
15	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	3.7	19
16	The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 674-687.	3.9	18
17	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	3.0	17
18	Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. <i>Research and Reports in Urology</i> , 2018, Volume 10, 205-217.	1.0	15

#	ARTICLE	IF	CITATIONS
19	&lt;p&gt;Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 3741-3749.	1.9	15
20	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 2104-2110.	7.0	15
21	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs, 2020, 38, 1807-1814.	2.6	14
22	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology, 2022, 40, 3301-3309.	1.6	14
23	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastaticÂcastration-resistant prostate cancer. Future Oncology, 2022, 18, 1185-1198.	2.4	10
24	Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy. Clinical Cancer Research, 2021, 27, 5-7.	7.0	7
25	An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 6619-6621.	7.0	6
26	Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 363-365.	3.9	5
27	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer and Prostatic Diseases, 2022, 25, 306-313.	3.9	5
28	A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree. Cancers, 2021, 13, 2399.	3.7	4
29	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncology, 2022, 18, 35-45.	2.4	4
30	Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. Oncologist, 2019, 24, 143-145.	3.7	3
31	PARP Inhibitors in Prostate Cancer: A Promise Delivered. European Urology Oncology, 2020, 3, 612-614.	5.4	2
32	Quest for Ideal Composite Biomarkers for Response to Immunotherapies. Clinical Cancer Research, 2020, 26, 5059-5061.	7.0	1
33	Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. Oncologist, 2020, 25, 186-188.	3.7	1
34	A 33 MHz Fast-Locking PLL with Programmable VCO and Automatic Band Selection for Clock Generator Application. Electronics (Switzerland), 2021, 10, 1743.	3.1	1
35	A Compact High-Performance 10-bit 30-Channel OLED Driver Using Switched Capacitor Circuit for High-Linearity Application. Journal of Circuits, Systems and Computers, 0, , 2250013.	1.5	1
36	Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. Oncologist, 2021, 26, 904-905.	3.7	1

#	ARTICLE	IF	CITATIONS
37	A Chopper-Embedded BGR Composite Noise Reduction Circuit for Clock Generator. Electronics (Switzerland), 2021, 10, 2257.	3.1	1
38	The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatinâ€ineligible Patients with Muscleâ€invasive Localized Urothelial Carcinoma. Oncologist, 2019, 24, 580-583.	3.7	0